Serum screening for detection of high-risk group for early-stage diffuse type gastric cancer in Japanese
Corresponding Author
Masanori Ito
Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan
Masanori Ito, Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima 734-8551, Japan. Email: [email protected]Search for more papers by this authorMasaharu Yoshihara
Health Service Center, Hiroshima University, Higashi-Hiroshima, Japan
Search for more papers by this authorShunsuke Takata
Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYoshihiro Wada
Department of Gastroenterology, National Hospital Organization, Higashi-hiroshima Medical Center, Higashi-Hiroshima, Japan
Search for more papers by this authorTaiji Matsuo
Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorTomoyuki Boda
Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorShinji Tanaka
Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKazuaki Chayama
Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorCorresponding Author
Masanori Ito
Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan
Masanori Ito, Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima 734-8551, Japan. Email: [email protected]Search for more papers by this authorMasaharu Yoshihara
Health Service Center, Hiroshima University, Higashi-Hiroshima, Japan
Search for more papers by this authorShunsuke Takata
Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYoshihiro Wada
Department of Gastroenterology, National Hospital Organization, Higashi-hiroshima Medical Center, Higashi-Hiroshima, Japan
Search for more papers by this authorTaiji Matsuo
Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorTomoyuki Boda
Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorShinji Tanaka
Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKazuaki Chayama
Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorAbstract
Background and Aim: Serum screening systems are beneficial for gastric cancer mass surveys; however, the marker for diffuse type gastric cancer (DGC) is not defined. We attempted to define the high-risk group for DGC by using serum markers of anti-Helicobacter pylori antibody and pepsinogens (PG).
Methods: Forty-two patients in the early stage of DGC and 511 controls were enrolled. Fasting serum samples were collected, and anti-H. pylori antibody and PG were evaluated. The risk for DGC was calculated.
Results: The prevalence of DGC was higher in H. pylori-positive patients (odds ratio [OR] = 4.3 in men, 9.6 in women). DGC prevalence was significantly higher in the PG1+ group in women (OR = 10.7); however, it was lower in the PG3+ group in both men and women. Patients with PG II ≥ 30 revealed a significantly higher risk for DGC. By combining factors, higher OR (OR = 12.5 in men, 42.7 in women) were obtained when we defined the risk group as H. pylori-positive, PG-negative, and having PG II ≥ 30.
Conclusion: The risk group for DGC can be defined by evaluating ordinary serum gastritis markers.
References
- 1 Matsuda T, Marugame T, Kamo K et al. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn. J. Clin. Oncol. 2009; 39: 850–8.
- 2 Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci. Publ. 2004; 157: 327–49.
- 3 Sakamoto H, Yoshimura K, Saeki N et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 2008; 40: 730–40.
- 4 Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988; 48: 3554–60.
- 5 Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J. Gastroenterol. 2010; 45: 1–8.
- 6 Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9: 245–53.
- 7 Oka S, Tanaka S, Kaneko I et al. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest. Endosc. 2006; 64: 877–83.
- 8 Yoshihara M, Hiyama T, Yoshida S et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand. J. Gastroenterol. 2007; 42: 760–4.
- 9 Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784–9.
- 10 Wada Y, Ito M, Takata S et al. Relationship between Helicobacter pylori tyrosine-phosphorylated CagA-related markers and the development of diffuse-type gastric cancers: a case-control study. Digestion 2010; 82: 10–17.
- 11
Kikuchi S,
Wada O,
Miki K
et al.
Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer
1994; 73: 2695–702.
10.1002/1097-0142(19940601)73:11<2695::AID-CNCR2820731108>3.0.CO;2-O PubMed Web of Science® Google Scholar
- 12 Yanaoka K, Oka M, Yoshimura N et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int. J. Cancer 2008; 123: 917–26.
- 13 Kiyohira K, Yoshihara M, Ito M et al. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J. Gastroenterol. 2003; 38: 332–8.
- 14 Miyamoto M, Haruma K, Yoshihara M et al. Five cases of nodular gastritis and gastric cancer: a possible association between nodular gastritis and gastric cancer. Dig. Liver Dis. 2002; 34: 819–20.
- 15 Kamada T, Miyamoto M, Ito M et al. Nodular gastritis is a risk factor for diffuse-type of gastric carcinoma in Japanese young patients. Gastroenterology 2004; 126: A456.
- 16 Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan. J. Gastroenterol. 2007; 42: 1–15.
- 17 Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 350–2.
- 18 Ito M, Takata S, Tatsugami M et al. Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J. Gastroenterol. 2009; 44: 365–71.
- 19 Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 2009; 151: 121–8.
- 20 Takenaka R, Okada H, Kato J et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment. Pharmacol. Ther. 2007; 25: 805–12.
- 21 Ogura K, Hirata Y, Yanai A et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J. Clin. Gastroenterol. 2008; 42: 279–83.
- 22 Asaka M, Kato M, Takahashi S et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Japanese Society for Helicobacter Research. Helicobacter 2010; 15: 1–20.
- 23 Yanaoka K, Oka M, Ohata H et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int. J. Cancer 2009; 125: 2697–703.
- 24 Yoshihara M, Sumii K, Haruma K et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am. J. Gastroenterol. 1998; 93: 1090–6.
- 25 Chandanos E, Rubio CA, Lindblad M et al. Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer 2008; 11: 168–74.
Citing Literature
